Startseite
Podcasts
The Daily Podcast
Why One Drug Company Held Back a Better Drug

Why One Drug Company Held Back a Better Drug

The Daily vor 3 Jahren

0:00

35:38

For decades, drugmakers have argued that patents are critical to
bringing new drugs to the market. But in 2004, when a promising
H.I.V. treatment emerged, Gilead Sciences decided to slow-walk
its release to maximize profit on the company’s existing patents.

Rebecca Robbins, who covers the pharmaceutical industry for The
Times, discusses one man’s case and how patents can create
perverse incentives to delay new and better drugs.

Guest: Rebecca Robbins, a business reporter covering the
pharmaceutical industry for The New York Times.

Background reading:

Gilead delayed a new version of a drug, allowing it to extend
the patent life of a blockbuster line of medications, internal
documents showed.

In August, an expert panel recommended the new daily pill
Descovy for H.I.V. prevention.

For more information on today’s episode, visit
nytimes.com/thedaily. Transcripts of each episode will be made
available by the next workday.

For more information on today’s episode, visit
nytimes.com/thedaily. Transcripts of each
episode will be made available by the next workday.

Subscribe today at nytimes.com/podcasts or on Apple Podcasts,
Spotify and Amazon Music. You can also subscribe via your
favorite podcast app here
https://www.nytimes.com/activate-access/audio?source=podcatcher.
For more podcasts and narrated articles, download The New York
Times app at nytimes.com/app.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for
information about our collection and use of personal data for
advertising.